Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
NCT06597734 · M.D. Anderson Cancer Center · PHASE2 · withdrawn · last registry update 2026-10-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “PI request” | – | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IDH1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-29Also stopped (withdrawn): Virginia Commonwealth University, Olutasidenib Investigational Agent Administration (NCT07130695)
- 2026-08-04Phase 3 first posted: UNICANCER, Futibatinib + Ivosidenib + Capecitabine (NCT07745296)
- 2026-07-17Phase 3 first posted: Nuvation Bio Inc., Safusidenib + Placebo (NCT07712757)
- 2026-06-01Also stopped (terminated): Northwestern University, Cytarabine + Filgrastim (NCT04250051)
- 2026-04-20Also stopped (terminated): Servier Bio-Innovation LLC, Ivosidenib + Nivolumab (NCT05921760)
- 2026-04-14Results posted on the registry: National Cancer Institute (NCI), Ensartinib + Erdafitinib (NCT03155620)
- 2026-03-25Results posted on the registry: National Cancer Institute (NCI), Ivosidenib (NCT04195555)
- 2026-02-12Results posted on the registry: Servier Bio-Innovation LLC, Ivosidenib + Nivolumab (NCT05921760)
- 2026-01-28Also stopped (withdrawn): Duke University, a drug against IDH1 (NCT06648473)
- 2025-12-09Results posted on the registry: Servier, Ivosidenib (NCT06081829)
- 2025-10-14Phase 3 first posted: Alliance for Clinical Trials in Oncology, Temozolomide + Vorasidenib (NCT07215910)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision